Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES | O14684 | 13/20 | 0.49 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.46 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.45 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.44 |
| ▸ | NR2E3 | Q9Y5X4 | 1/20 | 0.43 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13393208 | 0.92 | PTGES (0.48) | PTGESALOX5HDAC11NR2E3 | |
| SCHEMBL1971443 | 0.90 | PTGES (0.47) | PTGESALOX5HDAC11DGAT1NR2E3 | |
| SCHEMBL13393326 | 0.89 | PTGES (0.52) | PTGESALOX5HDAC11NR2E3 | |
| SCHEMBL16352208 | 0.88 | PTGES (0.52) | PTGESALOX5HDAC11 | |
| SCHEMBL1975093 | 0.87 | PTGES (0.48) | PTGESALOX5HDAC11NR2E3 | |
| SCHEMBL16364097 | 0.86 | PTGES (0.48) | PTGESHDAC11NR2E3 | |
| SCHEMBL16352227 | 0.86 | PTGES (0.56) | PTGESALOX5HDAC11 | |
| SCHEMBL16364370 | 0.86 | PTGES (0.50) | PTGESALOX5NR2E3 | |
| SCHEMBL13393299 | 0.85 | DGAT1 (0.48) | PTGESHDAC11DGAT1 | |
| SCHEMBL1338302 | 0.84 | PTGES (0.45) | PTGESALOX5HDAC11DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8916599-B2 | 1H-benz imidazole-5-carboxamides as anti-inflammatory agents | OREXO AB (SE) | 2014-12-23 | — | — | US | disclosed |
| US-20110312935-A1 | 1H-Benz Imidazole-5-Carboxamides As Anti-Inflammatory Agents | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-12-22 | — | — | US | disclosed |
| EP-2334652-A1 | 1H-BENZ IMIDAZOLE-5-CARBOXAMIDES AS ANTI-INFLAMMATORY AGENTS | Boehringer Ingelheim International GmbH (DE) | 2011-06-22 | — | — | EP | disclosed |
| WO-2010034796-A1 | 1H-BENZ IMIDAZOLE-5-CARBOXAMIDES AS ANTI-INFLAMMATORY AGENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110312935-A1 | 1H-Benz Imidazole-5-Carboxamides As Anti-Inflammatory Agents | MAPRE2, MAPRE1, H1-4 | PTGES 118/4885ALOX5 3175/4885HDAC11 158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.